TOKYO, Japan, Feb. 23 /CNW/ - Sosei Group Corporation ("Sosei"; TSE
Mothers Index: 4565), the biopharmaceutical company, today announced
that Sosei Co., Ltd., its wholly owned Japanese subsidiary, was granted
approval for its emergency contraceptive pill, NorLevo(R) TABLETS
0.75mg, by the Japan Ministry of Health, Labour and Welfare (MHLW).
NorLevo(R) has thus become the fist emergency contraceptive pill
available in Japan.
NorLevo(R) is an oral emergency contraceptive, which is taken within 72
hours after unprotected sexual intercourse or contraceptive failure to
prevent unwanted pregnancy. Its active ingredient, levonorgestrel, is
listed as an essential drug by WHO.
Sosei acquired the exclusive distribution rights to the product in Japan
and Australia from Laboratoire HRA Pharma in April 2001. NorLevo(R) was
first launched in Europe in 1999 and is currently approved in some 50
According to the distribution agreement, which Sosei signed with ASKA
Pharmaceutical Co., Ltd. in November 2009, ASKA will be responsible for
commercialization of NorLevo(R) in Japan and is expected to launch the
product in the middle of May 2011.
Notes for Editors:
Sosei is an international biopharmaceutical company anchored in Japan
with a global reach. It practises a reduced risk business model by
acquiring compounds from, and bringing compounds into, Japan through
exploitation of its unique position within global markets.
For further information about Sosei, please visit http://www.sosei.com.
About HRA Pharma
HRA Pharma is a privately-held European pharmaceutical company that
designs products, devices and supporting services in niche areas of
health and makes them available to doctors and patients worldwide. The
company targets therapeutic gaps in the areas of reproductive health
and endocrinology and uses innovative marketing solutions and
socially-conscious programs to promote healthy management of drugs and
diseases. Headquartered in Paris, France and with offices throughout
Europe, HRA Pharma has built a strong network of R&D, manufacturing,
distribution and NGO partners which enables it to satisfy critical
patient needs and improve patient health in over 50 countries across
the globe. Visit www.hra-pharma.com for more information.
Based on the corporate mission, "Contribute toward the improvement of
people's health and progress in medicine through the development of
innovative products," ASKA Pharmaceutical, as a focused research and
development (R&D) oriented company, concentrates its management
resources for the development of new products in defined areas to
develop and supply innovative and creative pharmaceutical products that
contribute broadly to society. With 934 employees (as of December 2010)
ASKA develops and commercializes products in areas of internal medicine
(digestive and cardiovascular organs, thyroid glands), urology,
otorhinolaryngology, and gynecology and obstetrics.
For further information about ASKA, please visit:
SOURCE Sosei Group Corporation
For further information:
Enquiries: Sosei Group Corporation, Tokyo Office, Hidetoshi TORAMI, Chief Financial Officer, +81(0)3-5210-3399, email@example.com; London Office, Yumi YAMAMOTO, Vice President, Finance and IR Europe, +44(0)20-7691-2081, firstname.lastname@example.org